Diagnostics, Laboratories & Clinical Research Marketing, AI & Growth Consulting
A test result can change a diagnosis. A pathology report can change a treatment plan. A biomarker can determine whether a therapy is even relevant. A clinical trial can move medicine forward—or spend months looking for participants nobody successfully helped find it.
I help diagnostic organizations, clinical and specialty laboratories, pathology groups, genomics companies, CROs, research sites, central labs, bioanalytical services and clinical-research organizations connect scientific credibility to referrals, sponsors, investigators, participants, enterprise accounts, AI search, SEO, websites, paid acquisition, technical content and growth.
The test, the evidence and the research question come first. Marketing has to understand enough of all three to know which audience actually matters.
The diagnostic economy is built around one deceptively hard question: does the result help somebody make a better decision?
More sensitivity is not automatically better if specificity collapses. More biomarkers are not automatically more useful if nobody knows what to do with them. A beautiful laboratory workflow is not commercially valuable if ordering physicians cannot understand when to use it. And a clinical trial is not accessible merely because its NCT number exists.
That is why I treat diagnostics, laboratories and clinical research as operating systems rather than collections of technologies. I want to understand the indication, method, specimen, regulatory status, ordering or sponsor workflow, interpretation, reimbursement or contract economics, turnaround, geographic reach, staffing, evidence and the next decision created by the result.
The strategy can then become specific. A pathology practice may need hospital contracts and referring specialists. A molecular lab may need physicians to understand test selection. A CRO may need sponsors. A site network may need studies and participants. A central lab may need global trial programs. A genomics company may need clinicians, researchers, pharma partners or all three.
The same specimen can move through medicine, research, technology and business.
A laboratory can need more volume and still be marketing the wrong test to the wrong person.
A diagnostic organization may have capacity and no physician awareness. Another may have plenty of orders and terrible payer mix. A specialty pathology group may have deep expertise that is invisible to hospital leadership. A clinical-research site may need more sponsor studies rather than more participant leads. A CRO can generate inbound traffic while failing to prove therapeutic expertise or delivery reliability to the sponsor teams that matter.
The same mistake appears repeatedly: marketing starts with the service name rather than the decision. “Molecular testing” is not a market strategy. Which disease? Which specimen? Which ordering professional? Which result? Which patient population? Which payer? Which clinical action? Which turnaround requirement? Which competitor or alternative?
I want to understand that system before choosing channels. Sometimes the growth constraint is discovery. Sometimes it is specimen logistics, contracting, reimbursement, investigator capacity, enrollment criteria, site activation, turnaround time, report usability or sales follow-up.
The U.S. laboratory and clinical-research environment is enormous—and currently easy to describe incorrectly if the source is two years old.
Sources: CMS CLIA, ClinicalTrials.gov Trends & Charts, and FDA Laboratory Developed Tests.
CLIA remains foundational
CMS regulates laboratory testing performed on humans in the United States through CLIA, except research testing. CLIA requirements are based on test complexity, and CMS describes the program's objective as ensuring accurate, reliable and timely patient test results.
LDT policy changed materially
FDA issued a final LDT rule in May 2024. A federal district court vacated that rule on March 31, 2025. FDA then issued a September 19, 2025 final rule reverting the affected IVD-definition text to the version that existed before the 2024 rule. Marketing copy written during the rollout period can therefore be badly stale now.
Clinical-trial standards modernized
FDA finalized ICH E6(R3) Good Clinical Practice in September 2025, emphasizing quality by design, proportionality, risk-based quality management, participant protection and flexibility for modern trial designs, data and technology.
Diagnostics and research businesses can look identical from the hallway and completely different on the income statement.
“Diagnostics” is not one market. It is a chain of decisions that begins before the sample and ends after the report.
General Clinical & Reference Laboratories
Clinical laboratories may compete on test menu, specimen logistics, turnaround, geographic reach, payer contracts, service, portal integration, physician support and the ability to handle volume reliably. For routine testing, operational excellence may matter more than exotic scientific differentiation.
Reference labs add another layer because their customers can be other laboratories, hospitals or specialty practices sending out testing they do not perform internally. The marketing audience is therefore often professional and operational rather than consumer.
Specialty Clinical Diagnostics
Specialty laboratories may build their value around a particular disease, method or physician population: endocrine testing, immunology, coagulation, therapeutic drug monitoring, specialty chemistry or another focused domain. The closer the test gets to a nuanced clinical decision, the more important interpretation and physician education become.
Search visibility can support discovery, but specialty diagnostics often grow through professional trust. The clinician needs to know when the test is useful, which specimen is required, what the report means, how quickly it returns and how it fits alongside other information.
Clinical Toxicology & Drug Testing
Drug testing can mean different things depending on the use. Presumptive immunoassay and definitive testing have different roles. Clinical monitoring is different from employment testing, forensic testing or sports testing. CMS coverage policies, payer rules, medical necessity and laboratory complexity can all affect the business.
Marketing should avoid suggesting that every positive or negative result answers more than the method can support. Clinical toxicology grows through appropriate use, credible interpretation and relationships with the professionals who need the information.
CLIA complexity is not a marketing tier. It changes what the laboratory has to operate.
CMS describes three broad test-complexity categories: waived, moderate and high complexity. As test complexity increases, personnel, quality and proficiency-testing requirements become more stringent. Moderate and high complexity laboratories have additional requirements around qualifications, oversight, quality systems and, for certain testing, proficiency testing.
A laboratory website should identify capabilities without casually claiming “CLIA certified” as if that tells the whole story. The actual certificate type, testing scope, accrediting relationships, state requirements and specialties can matter. Some states also maintain laboratory licensing requirements beyond federal CLIA.
This broader diagnostics and research strategy connects directly to my dedicated Laboratory Marketing Agency work, which focuses specifically on laboratories, laboratory technology, instruments, scientific software, LIMS/LIS/ELN, automation, technical SEO, AI discovery and laboratory demand generation.
Reference: CMS Clinical Laboratory Improvement Amendments and current 2026 CLIA Proficiency Testing information.
Pathology is sometimes invisible to the patient and central to nearly everything that happens next.
The pathologist may never meet the patient, yet the diagnosis can determine surgery, oncology treatment, additional testing or whether a suspected disease is present at all.
Anatomic pathology
Surgical pathology, histology and tissue diagnosis depend on specimen quality, processing, microscopy, interpretation, subspecialty expertise and communication with treating physicians. Hospital contracts may hinge on quality, access and turnaround as much as brand visibility.
Cytopathology
Cytology can involve cervical cytology, fine-needle aspiration and other specimen types. CLIA also contains specialized proficiency-testing requirements for individuals examining gynecologic preparations.
Molecular pathology
Molecular pathology connects morphology with DNA, RNA and other biomarkers. It may support diagnosis, prognosis, therapy selection and disease classification, particularly in oncology and inherited disease.
Dermatopathology
Dermatopathology combines dermatology and pathology. Referral relationships with dermatologists and surgeons can be central, and subspecialty expertise may matter more than consumer awareness.
Hematopathology
Blood and lymphoid malignancies may require morphology, flow cytometry, cytogenetics and molecular testing together. The marketing should show how the diagnostic system integrates rather than present each method as a separate miracle.
Pathology groups & hospital contracts
Independent pathology practices may market to health systems, surgery centers and physician groups. Staffing, subspecialty coverage, turnaround, medical-director capability and digital-pathology infrastructure can influence facility decisions.
The physician-business side also connects naturally with my Physician & Surgeon Marketing work, where pathology and radiology sit inside the broader facility-based and diagnostic physician economy.
The more information a test generates, the more important it becomes to explain what the information can actually do.
PCR & nucleic-acid testing
Molecular amplification can support infectious disease, genetics, oncology and many other applications. Method, target, specimen, limit of detection, intended use and workflow matter more than using “molecular” as a synonym for advanced.
Next-generation sequencing
NGS can interrogate panels, exomes, genomes or other targets. The commercial value depends on the clinical or research question, analytical pipeline, interpretation, turnaround, evidence and what action the result supports.
Inherited-disease testing
Genetic testing can affect the patient and biological relatives. Pretest context, informed decision-making, result interpretation and genetic counseling may be important depending on the service and jurisdiction.
Pharmacogenomics
PGx attempts to use genetic variation to inform medication-related decisions. The evidence and clinical recommendations vary by gene-drug pair, so marketing should not imply that one panel automatically selects the perfect medication for every patient.
Liquid biopsy
Circulating tumor DNA and other circulating analytes can support selected oncology uses. Sensitivity, tumor shedding, disease stage, tissue concordance, intended use and false-negative considerations can materially affect interpretation.
Multi-omics & computational interpretation
Genomics, transcriptomics, proteomics, metabolomics and other data can create biological insight while multiplying analytical complexity. Sometimes the most valuable product is not generating more data; it is making the data reliable enough to support a decision.
Precision oncology turns diagnostic access into part of therapeutic access.
If a therapy requires a biomarker, the healthcare system has to identify the patient before the therapy can be used appropriately.
Companion diagnostics
FDA defines a companion diagnostic as an IVD or imaging tool that provides information essential for the safe and effective use of a corresponding therapeutic product. Therapy and diagnostic labels are therefore connected.
Immunohistochemistry
Protein-expression assays can support diagnosis and therapy selection. Tissue quality, scoring, thresholds and interpretive context are part of real-world use.
NGS tumor profiling
Tissue and plasma NGS can identify selected genomic alterations associated with approved therapies, trials or broader tumor profiling. A detected alteration is not automatically a treatment recommendation.
MRD & ctDNA
Molecular residual-disease and ctDNA approaches are rapidly evolving across oncology. Intended use and evidence can differ across recurrence monitoring, treatment selection, trial endpoints and other applications.
Pathologist + oncologist workflow
Testing works commercially and clinically when tissue stewardship, ordering, report interpretation, turnaround and oncology decision-making fit together.
Therapy-test co-commercialization
Pharma and diagnostic organizations may need coordinated education so laboratories can perform or access the test and clinicians understand when testing belongs in the pathway.
FDA maintains a current list of FDA-authorized companion diagnostic devices, including 2026 additions across tissue and liquid-biopsy applications.
When the organism changes, speed, sensitivity and public-health context can change with it.
Molecular infectious-disease testing
PCR and multiplex molecular panels can accelerate detection, but broad panels can also produce findings that require clinical interpretation. Specimen, target and pretest probability remain important.
Culture & susceptibility
Conventional microbiology remains important for organism isolation, susceptibility testing and other questions that a rapid molecular result may not answer fully.
Antimicrobial resistance
Resistance detection connects microbiology, infectious disease, pharmacy, infection prevention and public health. Diagnostic communication can support stewardship without promising that every resistance mechanism predicts every clinical outcome.
Respiratory & outbreak testing
Seasonality, outbreaks and emerging pathogens can create sudden demand. Capacity, supply, reporting and test selection matter as much as media attention.
Public health laboratories
Public-health labs perform surveillance and specialized testing that may not fit a conventional commercial model. Mission, infrastructure, workforce and interagency communication shape their visibility needs.
Hospital microbiology
Hospital labs support infection diagnosis, isolation decisions, stewardship and infection prevention. The value is integrated into care delivery rather than sold like a retail test.
Moving the test closer to the patient changes more than the distance to the analyzer.
Point-of-care and home testing can improve convenience and speed, but they also shift responsibility toward simpler workflows, training, user interpretation and reliable next steps.
CLIA-waived testing
Waived tests are simpler under the CLIA complexity framework, but laboratories or testing sites still have applicable CLIA responsibilities and must follow the manufacturer's instructions for waived systems.
Physician-office testing
Tests near the point of care can shorten time to decision, but workflow, quality control, staffing and result integration determine whether the operational benefit is real.
Home-use diagnostics
Home tests bring labeling, human factors, consumer comprehension and follow-up into the product experience. A result without a clear next step can create anxiety instead of useful information.
Direct-to-consumer testing
Consumer-initiated diagnostics can involve laboratory services, devices or both. Marketing must be especially careful with disease-risk, wellness and treatment claims and with how results connect to medical care.
Remote specimen collection
At-home collection can improve reach, but specimen stability, shipping, identity, adequacy and rejection rates become part of the service experience.
Retail & pharmacy testing
Testing in pharmacies or other retail settings can expand access while creating a distinct referral and follow-up model from the traditional physician-office or hospital lab.
The slide can become pixels. The diagnostic responsibility does not disappear.
Whole-slide imaging
Digital pathology converts glass slides into high-resolution digital images that can support review, consultation, education and selected clinical workflows. Scanning quality, storage, displays, workflow and validation matter.
Computational pathology
Image analysis and AI can quantify features, support detection or assist interpretation depending on the product and intended use. Marketing should describe the authorized function rather than implying autonomous diagnosis when the system is assistive.
Radiology diagnostics
Imaging centers, radiology groups and AI imaging tools overlap with diagnostics but have their own equipment, referral, reimbursement and workflow systems. The physician side also connects to the broader healthcare practice and hospital markets.
Teleradiology & telepathology
Remote professional interpretation can expand coverage and subspecialty access. Credentialing, licensure, integration, turnaround and quality remain operational facts behind the digital experience.
AI confidence
Performance depends on the intended population, data, task and workflow. “AI-powered” is not a clinical validation method, and a model should not be marketed beyond its actual regulatory status.
Data infrastructure
Digital diagnostics can create large image and genomic datasets. Storage, interoperability, security and data governance become part of commercial credibility.
The laboratory is also an enterprise technology market.
Analyzers, automation, robotics, instruments, software and data systems can improve throughput, consistency and visibility—but only if they fit the method, people and workflow.
Clinical analyzers
Chemistry, hematology, immunoassay, microbiology, molecular and specialty systems sell through performance, menu, throughput, reliability, service and workflow fit.
Mass spectrometry
LC-MS/MS and other mass-spectrometry workflows can support toxicology, endocrinology, therapeutic monitoring, proteomics and research. Method development and laboratory expertise matter as much as instrument specifications.
Automation & robotics
Preanalytics, sample handling, liquid handling, track systems and robotic workflows can change labor, throughput, error exposure and standardization.
LIMS / LIS / ELN
Laboratory systems have different jobs. LIS commonly supports clinical lab workflows; LIMS can support sample, process and laboratory information management; ELNs support research documentation. The buying audiences overlap but are not interchangeable.
These technology markets are covered in much greater commercial specificity through Laboratory Marketing, with adjacent engineering context in Science Marketing and Frontier Science.
A clinical trial is a scientific protocol operating through human beings, institutions, data systems and calendars.
ClinicalTrials.gov listed 593,857 studies across 226 countries and territories in its July 14, 2026 snapshot. That scale explains why “find a clinical trial” can be simultaneously easy in theory and bewildering in practice.
FDA's September 2025 final E6(R3) Good Clinical Practice guidance modernized the GCP framework around quality by design, risk-based quality management, technology and flexible trial designs while preserving the core goals of participant protection and reliable results. Marketing and recruitment should fit inside that scientific and ethical structure, not sit beside it as a separate sales activity.
Reference: FDA — E6(R3) Good Clinical Practice, September 2025.
The sponsor is buying execution under uncertainty.
Full-service CROs
Large CROs may offer clinical operations, monitoring, data management, biostatistics, regulatory, pharmacovigilance and other functions. “End to end” means little unless the sponsor understands where the CRO is particularly strong.
Specialty CROs
Therapeutic-area, geography, phase, technology or service specialization can create a much sharper commercial position. A small oncology CRO does not need to sound like a global generalist to be credible.
Independent research sites
Sites need suitable studies, investigators, coordinators, participant access and operational delivery. Sponsor-facing marketing and participant-facing recruitment are different businesses inside the same organization.
Site networks
Networks can aggregate investigators, geography, therapeutic reach, standardized processes and centralized support. Their commercial promise is partly scale and partly reduced sponsor friction.
SMOs & site services
Site-management organizations can support operations, staffing, finance, recruitment and infrastructure. The value proposition should show what burden is actually removed from investigators or sponsors.
Academic research
Academic medical centers may prioritize scientific leadership, investigator-initiated studies, grants, publications and collaboration alongside commercial trials. The communication model is not the same as a private site network.
Clinical trials can turn a specimen into a multinational logistics project.
Central laboratories
Global or regional central labs can standardize testing across study sites, manage kits and specimens, integrate data and support protocol-specific workflows. Sponsor confidence depends on operational execution as much as assay capability.
Bioanalytical laboratories
PK, immunogenicity, biomarkers and other bioanalysis can support drug development. Method development, validation, sample stability, chain of custody, data integrity and regulatory expectations shape the value proposition.
Genomics & biomarker labs
Clinical trials increasingly use genomic and molecular biomarkers for eligibility, stratification, pharmacodynamics or exploratory endpoints. The lab may become part of patient selection as well as research.
Central pathology
Central pathology review can support eligibility, endpoints and consistency across sites. Digital pathology can expand access to expert review while creating image-management and validation requirements.
Flow cytometry
Advanced flow can support immunophenotyping, hematology, cellular therapy and pharmacodynamic work. Panel design, sample handling, standardization and interpretation can materially affect data quality.
Data integrity
FDA continues to emphasize sponsor responsibility for study-data integrity and has issued public notifications when clinical or bioanalytical studies were deemed unacceptable. A research vendor's reputation depends on defensible data, not just turnaround.
Reference: FDA Notifications on Data Integrity.
A person is not a recruitment conversion after informed consent. They are a participant making an ongoing decision to stay involved.
Trial recruitment can involve physician referrals, patient advocacy, site databases, search, social media, community outreach, health-system records and direct digital campaigns. But eligibility can be narrow, and marketing metrics can look wonderful while the screening funnel quietly collapses.
I prefer to track awareness, qualified inquiry, prescreen, formal screening, consent, enrollment, randomization where applicable, retention and completion. The step that matters most depends on the protocol. Cost per lead by itself can reward campaigns that attract large numbers of people who were never likely to qualify.
Recruitment also belongs inside the informed-consent environment. FDA's informed-consent guidance notes that recruitment advertising is considered part of the consent process, while basic trial listings containing limited factual information are treated differently. IRB review and sponsor/site procedures matter.
FDA finalized guidance in December 2025 on enhancing participation in clinical trials, encouraging eligibility and enrollment approaches that better reflect the populations likely to use a drug if approved. Recruitment strategy should therefore consider who is missing from access, not only who is cheapest to reach.
References: FDA Informed Consent Guidance and FDA Enhancing Participation in Clinical Trials, December 2025.
Moving part of the trial out of the research site can reduce burden—and create a new collection of things that have to work.
FDA's final September 2024 decentralized-trials guidance recognizes remote elements including telehealth visits, in-home visits and visits with local healthcare providers.
Telehealth visits
Remote investigator or study-team interactions can reduce travel when clinically and operationally appropriate. Technology, identity, documentation and escalation processes still matter.
Home health / local providers
Some protocol activities may occur closer to participants. Training, delegation, data flow and responsibilities need to remain clear across distributed personnel.
Direct-to-patient logistics
Investigational-product shipping, specimen kits, devices and supplies can reduce site burden while increasing logistics, temperature, chain-of-custody and support requirements.
Digital health technologies
Wearables, sensors, eCOA and remote measures can collect data outside the site. Fit-for-purpose validation and participant usability influence whether the data are useful.
Hybrid trials
Many practical trials mix site-based and remote elements rather than being entirely virtual. Recruitment should explain what participation actually requires instead of advertising “study from home” too broadly.
Participant burden
Remote does not automatically mean easy. Devices, apps, shipping, connectivity, caregiving and home procedures can create new forms of burden that affect retention.
Reference: FDA — Conducting Clinical Trials With Decentralized Elements.
The test result or trial observation becomes evidence only after the data survive everything that happens next.
Data management
EDC, source data, queries, coding, reconciliation and database controls influence whether study data remain usable. Technology can accelerate the process but does not eliminate protocol discipline.
Biostatistics
Study design, estimands, analysis populations, missing data, multiplicity, power and uncertainty shape the conclusions that can legitimately be drawn. Marketing should never rewrite statistical nuance into certainty.
Real-world data / evidence
Electronic health records, claims, registries and other real-world sources can support research and regulatory questions when data relevance and reliability are fit for purpose.
Registries
Disease and product registries can support natural history, outcomes, safety and postmarket learning. Longitudinal participation and data completeness are often the hard part.
Clinical outcome assessments
Patient-reported, clinician-reported, observer-reported and performance measures can capture outcomes that matter beyond a laboratory value. The measure has to fit the concept of interest and context of use.
AI and analytics
Machine learning can support data review, imaging, biomarker discovery and operational analytics. It should not obscure source traceability, bias, validation or human accountability.
Diagnostic and research search often begins with a method, biomarker, disease or protocol problem rather than a company name.
Clinical search
Physicians may search test indications, biomarkers, sample requirements, specialty labs, turnaround or interpretation. Patients may search a diagnosis, genetic test, pathology service or how to access testing.
Sponsor / research search
Biotech and pharma teams may search central labs, bioanalytical methods, specialty CROs, sites, therapeutic expertise, imaging cores or assay capabilities.
Technical search
Scientists may search methods, instruments, analytes, validation, matrices, sensitivity, sample stability or specific technologies before any vendor shortlist exists.
Trial search
Participants and clinicians may search disease, location, treatment, sponsor, phase or eligibility concepts. Trial content needs enough plain language to be found without turning eligibility into a marketing promise.
AI answer visibility
Clear relationships among test, biomarker, disease, specimen, method, laboratory, provider, study, sponsor and regulatory status help answer systems understand what the organization actually does.
Entity precision
A diagnostic company, pathology practice, CLIA laboratory, CRO and research site should not all describe themselves as “healthcare innovators.” The entity type itself is useful information.
Some laboratory and research markets have enormous audiences. Others have 40 sponsor teams worth knowing by name.
Account-based sponsor growth
Central labs, CROs, specialty research vendors and technology companies can identify priority biotech and pharma accounts and build technical content around the programs and decision-makers most likely to need them.
Physician acquisition
Diagnostic laboratories may use professional search, targeted campaigns, field outreach and educational content to reach physicians who can order appropriate testing.
Patient / participant paid media
Direct campaigns can support access or trial recruitment, but health-data sensitivity, claims, eligibility, IRB requirements and platform policy require more discipline than ordinary lead generation.
Conference demand
Pathology, genomics, laboratory medicine and clinical-research conferences can concentrate highly qualified professional audiences. Appointment generation and technical follow-up should begin before the event.
Retargeting with restraint
Someone researching a rare disease, genetic condition or clinical trial may be in a highly sensitive situation. Audience design should not make people feel followed around the internet by their diagnosis.
CRM and qualification
Lab sales and sponsor business development need lead qualification that distinguishes physicians, patients, vendors, researchers, sponsors and job seekers rather than dumping every form into one queue.
A diagnostic website should explain the result pathway. A research website should explain the study pathway.
Test directories
Organize tests by clinical question, specialty, analyte or other useful taxonomy; include specimen, methodology, turnaround and ordering information where appropriate.
Provider pathways
Ordering, account setup, requisitions, logistics, coverage basics and professional support should be easier to find than a generic sales form.
Participant pathways
Study purpose, major participation requirements, locations, contact, visit expectations and next steps should be understandable before someone enters screening.
Sponsor pathways
CRO and research-vendor sites should surface therapeutic expertise, capabilities, geographies, metrics, technology and business-development contacts.
Patient results experience
Portals and reports should help users understand what the result is, what it does not mean and where clinical interpretation or follow-up belongs.
Technical resources
Validation summaries, methods, publications, posters, specimen guides and scientific resources can support professional confidence without forcing every visitor into the deepest technical layer.
Accessibility
Research participants and patients may have disabilities, illness, fatigue or anxiety. Accessible digital design is not polish; it is part of access.
WordPress where appropriate
I can build sophisticated WordPress systems for many organizations. Lab portals, regulated systems and enterprise research technology may require specialized platforms beyond the public website.
Explore integrated digital strategy, websites and technical marketing →
“Detects,” “diagnoses,” “screens,” “predicts,” “monitors” and “supports research” are not synonyms.
Diagnostic language changes what the audience believes the test can do. Research language changes what a participant believes is known.
Analytical performance
Sensitivity, specificity, precision, limit of detection, reproducibility and other analytical characteristics answer method-performance questions. They do not automatically establish clinical utility.
Clinical validity
A test may accurately identify an analyte while the association between that analyte and a clinical condition has its own strength, limitations and population context.
Clinical utility
Whether using a test improves decision-making or outcomes can be a different question again. Marketing should not skip from “the analyte can be measured” to “therefore patients benefit.”
LDT language
The federal LDT policy landscape changed materially in 2025. Specific statements about FDA oversight, exemptions or test status should be reviewed against current law and facts rather than copied from 2024 marketing material.
Research participation
Recruitment should not imply that an investigational intervention is proven treatment. Benefit is uncertain by definition in research, and participants may or may not benefit personally.
Privacy
Genomic data, pathology results, trial eligibility and diagnostic information can be intensely sensitive. HIPAA may apply in some relationships; research consent, authorization, state laws and contractual requirements may add additional obligations.
Test volume is useful. Appropriate test volume is much more interesting.
| Metric | What it can tell me | What it cannot tell me alone |
|---|---|---|
| Qualified ordering accounts | Whether physician practices, hospitals or organizations with appropriate need are entering the pipeline. | Actual ordering volume, payer fit or clinical appropriateness. |
| Test volume by service line | Which assays, specialties or referral channels are growing. | Margin, denial rate, utilization quality or downstream clinical value. |
| Turnaround / service performance | Whether the operational promise is being delivered consistently. | Clinical quality or customer satisfaction. |
| Sponsor opportunities | Whether CRO, central-lab or research marketing is creating relevant study conversations. | Study award probability or program economics. |
| Screen-to-enrollment rate | How well recruitment is finding participants who actually meet protocol criteria. | Site execution, participant burden or retention. |
| Retention / completion | Whether enrolled participants remain engaged through required study activity. | Why discontinuation occurs or whether withdrawal is clinically appropriate. |
| Referral-source quality | Which physicians, sites, advocates, search channels or partners produce useful volume. | Long-term relationship strength or scientific reputation. |
Specimens travel. Participants travel. Scientific expertise clusters. Those three facts create very different maps.
Geography matters where it changes referral density, sample stability, courier routes, specialty access, site recruitment, research institutions, sponsor proximity or participant burden.
DeLand, Volusia & Central Florida
Central Florida combines a large and growing patient base, hospitals, physician networks, research activity, universities and easy regional transportation. Local diagnostics may depend heavily on physician relationships and courier practicality rather than broad consumer marketing.
Florida
Florida's population size, older-adult population, diverse communities, oncology and specialty-care demand and research footprint can support diagnostics and clinical trials. Participant-recruitment strategy should still be built around the actual protocol rather than assuming “Florida” is one audience.
National research hubs
Boston/Cambridge, Research Triangle, New York/New Jersey, Philadelphia, San Diego, the Bay Area and other research clusters concentrate sponsors, academic medicine, biotech, CROs and specialized talent. Business-development geography may therefore differ sharply from patient geography.
Bring me the test menu, protocol, sponsor problem, referral problem or technical mess.
Maybe the laboratory ranks well and the wrong tests are growing. Maybe the pathology group is excellent and hospital executives cannot tell why it is different. Maybe the CRO site has investigators and no sponsor pipeline. Maybe participant campaigns generate hundreds of leads and almost nobody screens in. Maybe a genomics company has beautiful science and a report nobody knows how to use. Maybe a central lab sells global capability through a website that looks like a local blood-draw center.
I work with laboratory leaders, scientists, physicians, founders, CRO executives, site networks, clinical teams, marketing leaders, business development and technical operators. Sometimes I am the outside strategist. Sometimes I work more like a fractional CMO. Sometimes I own search, AI visibility, content, websites, paid acquisition, analytics or implementation directly.
I do not provide laboratory-director, regulatory, clinical-trial, biostatistical, medical, legal or compliance services. My job is to understand enough of those systems that the marketing, growth and communication strategy respects what the real experts need to protect.
Diagnostics, laboratory & clinical research marketing FAQs
The useful questions usually begin with the test, specimen, protocol, evidence or next decision—not the channel.
What does a diagnostics and clinical research marketing consultant do?
I help diagnostic organizations, laboratories, pathology groups, genomics companies, CROs, clinical-research sites and research vendors connect scientific positioning, referrals, sponsors, participant recruitment, SEO, AI search, websites, paid media, business development and measurement to the real clinical or research workflow.
How is this different from your Laboratory Marketing Agency work?
My Laboratory Marketing Agency work focuses specifically on laboratory commercialization, clinical and diagnostic labs, analytical testing, instruments, laboratory automation, LIMS, LIS, ELN, scientific software and laboratory demand generation. This broader diagnostics and clinical-research work connects laboratories to pathology, genomics, precision medicine, CROs, sites, trials, participant recruitment and research infrastructure.
Do you work with clinical laboratories?
Yes. Clinical-laboratory strategy can include physician referrals, hospital relationships, test-menu positioning, technical SEO, AI search, specimen and logistics education, payer communication, account growth, websites, reputation and business development. Actual laboratory compliance and clinical decisions remain with qualified laboratory professionals.
What does CLIA regulate?
CMS regulates laboratory testing performed on humans in the United States through the Clinical Laboratory Improvement Amendments program, except research testing. CLIA's objective is quality laboratory testing, and requirements become more stringent as test complexity increases.
How many laboratories are covered by CLIA?
CMS currently states that CLIA covers approximately 320,000 laboratory entities in the United States.
What are waived, moderate and high-complexity laboratory tests?
CLIA categorizes testing by complexity. Waived tests are simpler systems that meet waiver criteria. Moderate and high-complexity testing carry progressively more stringent requirements around personnel, quality and oversight. FDA categorizes commercially marketed test systems for CLIA complexity.
What happened to FDA's 2024 laboratory-developed-test rule?
A federal district court vacated FDA's May 2024 LDT final rule on March 31, 2025. FDA then issued a September 19, 2025 final rule reverting the affected in vitro diagnostic definition to the wording that existed before the 2024 rule. Specific current LDT regulatory questions should be reviewed with qualified regulatory counsel.
Can you help pathology groups?
Yes. Pathology strategy can include hospital and surgery-center contracts, subspecialty authority, dermatopathology, molecular pathology, hematopathology, physician relationships, turnaround, digital pathology, professional visibility and recruitment.
Can you help molecular and genomic diagnostic companies?
Yes. Strategy can address PCR, NGS, inherited-disease testing, oncology panels, pharmacogenomics, liquid biopsy, bioinformatics and other molecular applications. The messaging should distinguish analytical performance, clinical validity, clinical utility and the intended clinical or research use.
Can you help precision-oncology and companion-diagnostic companies?
Yes. Companion diagnostics connect biomarker testing to therapeutic use. Commercial strategy may need to reach laboratories, pathologists, oncologists, pharma partners, health systems and patients while making testing workflow and treatment relevance understandable.
What is a companion diagnostic?
FDA describes a companion diagnostic as an in vitro diagnostic or imaging tool that provides information essential for the safe and effective use of a corresponding therapeutic product.
Can you help liquid-biopsy companies?
Yes. Liquid-biopsy strategy can address circulating tumor DNA and other analytes, sample type, intended use, assay evidence, oncology workflow, pathologist and oncologist education, payer context and the limitations that affect interpretation.
Can you help infectious-disease and microbiology laboratories?
Yes. Strategy can address molecular diagnostics, culture, susceptibility testing, respiratory testing, antimicrobial resistance, hospital microbiology, public-health relationships and physician education while keeping method and clinical-use claims accurate.
Can you help toxicology and drug-testing laboratories?
Yes. Clinical toxicology can involve presumptive and definitive testing, pain medicine, behavioral health and other medical applications. Employment, forensic and clinical drug testing have different regulatory and commercial contexts and should not be presented as interchangeable.
Can you help point-of-care testing companies?
Yes. Point-of-care strategy can involve test performance, workflow, CLIA categorization, physician-office or retail use, training, integration, turnaround and the clinical decision the faster result is intended to support.
Can you help direct-to-consumer and home-testing companies?
Yes, when the claims, regulatory status and service model are clear. DTC and home diagnostics require especially strong consumer education, human factors, privacy awareness and a sensible path for interpretation or medical follow-up.
Can you help digital pathology companies?
Yes. Digital-pathology strategy can address whole-slide imaging, workflow, scanners, image management, computational pathology, AI, remote consultation, pathologist adoption and hospital or laboratory integration.
Can you help CROs market to biotech and pharmaceutical sponsors?
Yes. CRO strategy can focus on therapeutic expertise, phases, geographies, operations, monitoring, data management, biostatistics, regulatory capabilities, specialty services, case evidence, ABM and sponsor business development.
Do you work with clinical research sites and site networks?
Yes. Research sites need two distinct growth systems: sponsor-facing business development to win appropriate studies and participant-facing recruitment to enroll and retain qualified participants. Site networks also need to communicate standardized operations, geographic reach, investigators and delivery performance.
Can you help clinical research sites win more studies?
Yes. Sponsor-facing strategy can include therapeutic-area positioning, investigator profiles, site metrics, participant access, facility capabilities, prior performance, search visibility, conference strategy, ABM and business-development content.
Can you help with clinical trial participant recruitment?
Yes, from the marketing and communication side. I can help with search, paid media, patient-friendly study information, referral pathways, prescreen funnels, local outreach and measurement. Eligibility, informed consent, IRB review and clinical conduct remain with the sponsor, investigators and qualified research professionals.
How should clinical trial recruitment be measured?
I prefer to track progression from awareness and inquiry through prescreen, formal screening, consent, enrollment, randomization where applicable, retention and completion. Cost per lead alone can reward campaigns that generate large numbers of people who cannot qualify.
Does FDA consider clinical-trial recruitment advertising part of informed consent?
FDA's informed-consent guidance states that recruitment advertising is considered part of the informed-consent process. Basic factual trial listings are treated differently, while materials that go beyond basic information may require IRB review under applicable procedures.
What is E6(R3) Good Clinical Practice?
FDA finalized ICH E6(R3) Good Clinical Practice in September 2025. It modernizes GCP with quality-by-design, risk-based quality management, flexibility for modern trial designs and technology, clarified responsibilities and continued emphasis on participant protection and reliable results.
Can you help decentralized and hybrid clinical trials?
Yes. FDA's final decentralized-trial guidance recognizes remote elements such as telehealth visits, in-home visits and visits with local healthcare providers. Marketing can help participants understand the actual burden and workflow without implying that a hybrid protocol can be completed entirely from home.
Can you help companies using wearables and digital health technologies in trials?
Yes. Digital health technologies can support remote data collection and trial operations. Strategy can address participant usability, device logistics, data flow, clinical context and communication while leaving fit-for-purpose validation and regulatory decisions to qualified teams.
Can you help central laboratories and bioanalytical CROs?
Yes. Central and bioanalytical laboratory strategy can include PK, biomarkers, immunogenicity, sample logistics, genomics, flow cytometry, pathology, global study support, sponsor ABM, scientific content and technical search.
Can you help clinical-trial imaging and central pathology providers?
Yes. Central imaging and pathology services can support eligibility, endpoints, blinded review and consistency across sites. Strategy can focus on therapeutic expertise, technology, readers, workflow, quality and sponsor confidence.
Can you help biostatistics, data-management and real-world-evidence companies?
Yes. These organizations sell expertise and reliability rather than a simple product. Marketing can explain study design, data operations, RWE capabilities, registries, analysis and evidence-generation services without oversimplifying the statistical or scientific work.
How big is ClinicalTrials.gov?
ClinicalTrials.gov reported 593,857 registered studies with locations in all 50 U.S. states and 226 countries and territories as of July 14, 2026.
Can you provide SEO for diagnostic and clinical research organizations?
Yes. SEO can cover diseases, tests, biomarkers, methods, specimens, pathology specialties, research services, therapeutic areas, clinical-trial questions, sponsor capabilities and technical workflows while protecting against thin pages that merely repeat terminology.
Can you help diagnostic organizations appear in AI search?
Yes. GEO, AEO and AI Search Optimization can clarify the relationships among tests, diseases, biomarkers, methods, laboratories, physicians, trials, sponsors and regulatory status so answer systems can represent the organization more accurately.
Can you manage PPC for laboratories and clinical research?
Yes, when paid acquisition fits the business and applicable rules. Laboratory campaigns may target physicians, patients or enterprise buyers. Research campaigns may target sponsors or participants. Each audience requires different measurement and privacy safeguards.
Can you redesign a diagnostic or clinical-research website?
Yes. I can structure test directories, physician resources, specimen information, trial finders, sponsor capabilities, investigator profiles, technical resources, publications, forms, accessibility and analytics. Portals and regulated systems may require specialized platforms beyond the public marketing site.
Can you help laboratory and research organizations recruit scientists and clinical staff?
Yes. Employer positioning, careers architecture, scientific reputation, investigator visibility, location, professional development and specialty roles can all influence recruiting. Growth plans should account for whether staffing is the real capacity constraint.
Do you work with hospitals and academic medical centers on diagnostics and research?
Yes. Hospitals may need strategy around laboratory service lines, pathology, imaging, clinical research, participant access, physician referrals and enterprise reputation. Academic centers may also need investigator, collaboration and research-program visibility.
Do you only work with diagnostics and research organizations in Florida?
No. Paper Boat Media is based in DeLand, Florida, and I understand Central Florida and Florida healthcare markets especially well, but diagnostics and clinical research are national and often global. Geography matters when it changes referral density, specimen logistics, research sites, participant access, sponsors or scientific clusters.
Can you work as a consultant, fractional CMO or hands-on growth partner?
Yes. Engagements can range from focused audits and positioning projects to retained advisory, fractional CMO leadership and hands-on implementation across search, AI visibility, content, websites, paid media, participant recruitment, sponsor business development and analytics.
What should I bring to an initial diagnostics or research strategy conversation?
Bring the test, service or study model, current evidence and regulatory context, major audiences, payer or sponsor economics, capacity constraints, referral or enrollment funnel and the problem that is not working. I would rather start with the real operating system than a polished marketing brief.
Tell me what needs to get ordered, referred, sponsored, enrolled or understood.
Maybe the lab needs better physician accounts. Maybe pathology needs hospital visibility. Maybe the central lab needs sponsors. Maybe trial recruitment is producing interest rather than eligibility. Maybe a genomics company has more data than story. Maybe the CRO's website says “end to end” forty times and still does not explain why a sponsor should trust it.
Bring me the scientific question, the business model and the point where the system is getting stuck. I can work backward from there.